Latest ACE inhibitor Stories
A mutation in a gene that helps regulate high blood pressure is a cause of inherited kidney disease, according to a new study by researchers at Wake Forest University School of Medicine, Charles University in Prague and colleagues.
Proven beneficial to the heart and kidneys, research shows certain blood pressure drugs called ACE inhibitors may also benefit the brain.
Fixed-dose combination offers a convenient option that may help patients reduce steps to reach their blood pressure goals while decreasing patient pill burden(1) PARSIPPANY, N.J., May 13 /PRNewswire/ -- Daiichi Sankyo, Inc.
A newly published study found patients actually have more control of their high blood pressure (hypertension) when treated with less medication.
Researchers in Canada are reporting evidence that eggs â€” often frowned upon for their high cholesterol content â€” may reduce another heart disease risk factor â€” high blood pressure.
By Gutierrez, Orlando M Tamez, Hector; Bhan, Ishir; Zazra, James; Tonelli, Marcello; Wolf, Myles; Januzzi, James L; Chang, Yuchiao; Thadhani, Ravi BACKGROUND: Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are associated with increased cardiovascular mortality in chronic hemodialysis patients.
31 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor(R) reduced mortality and morbidity in patients with congestive heart failure (CHF).
By John von Radowitz Commonly used blood pressure drugs could prove to be powerful new weapons against Alzheimer's, new research has suggested. Scientists found that the drugs, known as angiotensin receptor blockers (ARBs), both prevented the disease occurring and slowed its progression.
By Forfia, Paul R Mathai, Stephen C; Fisher, Micah R; Housten-Harris, Traci; Hemnes, Anna R; Champion, Hunter C; Girgis, Reda E; Hassoun, Paul M Rationale: Hyponatremia is associated with decompensated heart failure and poor prognosis in patients with left ventricular systolic dysfunction.
BASEL, Switzerland and BRIDGEWATER, N.J., Dec. 19, 2006 (PRIME NEWSWIRE) -- Speedel (SWX:SPPN) announced today that in the interests of patient safety it has stopped the current pivotal Phase III clinical trial of SPP301 (Avosentan) in diabetic nephropathy (diabetic kidney disease).
- A poem in which the author retracts something said in an earlier poem.